Childhood Myelodysplastic Syndrome.
Chisholm KM, Bohling SD.
Clin Lab Med. 2023 Dec;43(4):639-655. doi: 10.1016/j.cll.2023.06.005. Epub 2023 Aug 7.
The Molecular Pathology of Myelodysplastic Syndrome.
Haferlach T.
Pathobiology. 2019;86(1):24-29. doi: 10.1159/000488712. Epub 2018 May 23.
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
Lee P, Yim R, Yung Y, Chu HT, Yip PK, Gill H.
Int J Mol Sci. 2021 Sep 23;22(19):10232. doi: 10.3390/ijms221910232.
MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
Baidurin S, Akhmetzhanova S, Ilmalieva A, Sagyndykova G, Orazbekova A.
Georgian Med News. 2023 Jan;(334):103-107.
[Myelodysplastic syndrome : prognostic factors].
Gyan E, Thépot S.
Bull Cancer. 2023 Nov;110(11):1141-1146. doi: 10.1016/j.bulcan.2023.06.008. Epub 2023 Aug 1.
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
Battaglia MR, Cannova J, Madero-Marroquin R, Patel AA.
Curr Treat Options Oncol. 2024 Jun;25(6):752-768. doi: 10.1007/s11864-024-01217-0. Epub 2024 May 30.
EnvIRONmental Aspects in Myelodysplastic Syndrome.
Petzer V, Theurl I, Weiss G, Wolf D.
Int J Mol Sci. 2021 May 14;22(10):5202. doi: 10.3390/ijms22105202.
Inflammation in myelodysplastic syndrome pathogenesis.
Rodriguez-Sevilla JJ, Colla S.
Semin Hematol. 2024 Dec;61(6):385-396. doi: 10.1053/j.seminhematol.2024.09.005. Epub 2024 Sep 21.
Familial myelodysplastic syndrome/acute myeloid leukemia.
Churpek JE.
Best Pract Res Clin Haematol. 2017 Dec;30(4):287-289. doi: 10.1016/j.beha.2017.10.002. Epub 2017 Oct 4.
Summary of animal models of myelodysplastic syndrome.
Li W, Li M, Yang X, Zhang W, Cao L, Gao R.
Animal Model Exp Med. 2021 Feb 3;4(1):71-76. doi: 10.1002/ame2.12144. eCollection 2021 Mar.
